KRAS and neoplasm: The results were consistent with the clinical association between tumour vascularity and metastasis arising as consequences of a tumour genotype – for example a k-ras or p53 (Rak et al, 1995; Bartsch et al, 1998; Maehara et al, 2000; Mehta et al, 2001) mutation – that associated increased tumour vascularity with metastatic phenotype.